HEAD-TO-HEAD STUDY SHOWS ORAL FERRIC MALTOL (FERACCRU®) MAY BE AN ALTERNATIVE TREATMENT TO INTRAVENOUS (IV) FERRIC IRON, OFFERING A REAL ALTERNATIVE OPTION TO HOSPITAL ADMINISTRATION FOR PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INACTIVE INFLAMMATORY BOWEL DISEASE (IBD)
22 October 2019
At Norgine, we are dedicated to developing, manufacturing and marketing innovative products that deliver value and improve patient’s lives. This is at the heart of our responsibility to patients, healthcare systems and society.
We are committed to professional practice and embrace ethical conduct and transparency in all of our activities. Effectively this means striving to achieve superior performance in all areas of our business and in our relationships with employees, patients, healthcare professionals, hospitals, payers, governments, business partners, competitors and all those with whom we interact on a daily basis.
We all share responsibility for upholding the Norgine Business Code which reflects the basic principles of respect, fairness and integrity which Norgine has embodied for the past century. This, coupled with the recognition that innovation and continuous improvement in quality, will ensure we responsibly deliver Norgine’s vision.